Back to top

Image: Bigstock

Falling Earnings Estimates Signal Weakness Ahead for MiMedx Group (MDXG)

Read MoreHide Full Article

Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share price and estimates are falling, it could be time to get rid of the security before more losses hit your portfolio.

One such stock that you may want to consider dropping is MiMedx Group, Inc. , which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year. A Zacks Rank #4 (Sell) further confirms weakness in MDXG.

A key reason for this move has been the negative trend in earnings estimate revisions. For the full year, we have seen one estimate moving down in the past 60 days, compared with no upward revisions. This trend has caused the consensus estimate to trend lower, going from 15 cents a share a month ago to its current level of 12 cents.

Also, for the current quarter, MiMedx Group has seen one downward estimate revision versus no revisions in the opposite direction, dragging the consensus estimate down to 4 cents a share from 7 cents over the past 30 days.   

The stock also has seen some pretty dismal trading lately, as the share price has dropped 8.1% in the past month.

MiMedx Group Inc. Price and Consensus

So it may not be a good decision to keep this stock in your portfolio anymore, at least if you don’t have a long time horizon to wait.

If you are still interested in the Medical - Biomedical and Genetics industry, you may instead consider a better-ranked stock – Dimension Therapeutics, Inc. . The stock currently holds a Zacks Rank #1 (Strong Buy) and may be a better selection at this time. You can see the complete list of today’s Zacks #1 Rank stocks here.

The Best Place to Start Your Stock Search

Today, you are invited to download the full, up-to-the-minute list of 220 Zacks Rank #1 "Strong Buy" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research. See these stocks free >>


See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


MiMedx Group, Inc (MDXG) - free report >>

Published in